Sovutrecdeg
Sovutrecdeg is a tropomyosin receptor kinase (TRK) degrader with antitumor activity. Sovutrecdeg can be used in tumor-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2412058-69-4
- Formule: C47H47F2N9O6
- Masse moléculaire:871.93
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Chemical Information
-
CAS No. 2412058-69-4
-
Masse moléculaire 871.93
-
Formule C47H47F2N9O6
-
SMILES
O=C(C1=CC=C(N2CCN(CC3CN(C3)C4=CC=C5C(N(C6C(NC(CC6)=O)=O)C(C5=C4)=O)=O)CC2)C=C1NC7CCOCC7)NC8=NNC9=C8C=C(CC%10=CC(F)=CC(F)=C%10)C=C9
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)